Project Grant R21EY035970
Award Date 9/15/25
Completion Date 8/31/27
Dollars Obligated $296K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $583,250 to The Schepens Eye Research Institute, Inc. to identify the mechanisms underlying ocular toxicity caused by nitrogen mustard exposure and evaluate specialized lipid mediators as potential medical countermeasures. The key objectives are to: 1) Determine how nitrogen mustard alters the function of conjunctival goblet cells and if...
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) will provide $937,468 to Northwestern University to understand the pathological mechanisms of sulfur mustard gas keratopathy (MGK) in the cornea. The research aims to explore how corneal mustard exposure induces autophagy, a cellular process that can play detrimental roles, via liberating the protein Beclin1 from the Beclin1-Bcl2 complex. The project will conduct in vitro and in...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support (CFDA 93.310) program provides $498,248 to the University of Connecticut Health Center (UCHC) to investigate the molecular mechanisms underlying corneal and retinal injury caused by exposure to chemical threat agents like nitrogen mustard. The key objectives are to: 1) Examine the role of the p53-PAD axis in driving corneal hypercitrullination, a pathological response, after nitrogen...
- This Project Grant award from the Department of Health and Human Services' National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,467,198.00 to the University of Connecticut Health Center (UCHC) to investigate the cellular and molecular mechanisms of corneal and sensory nerve damage caused by exposure to chemical warfare agents. The key products and services to be delivered under this 3-year award, which runs from September 15, 2025 to August...
- The Schepens Eye Research Institute, Inc. was awarded a $1,475,676 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2022 to August 31, 2025 to develop concomitant topical treatments for pain and inflammation resulting from ocular injuries. The Military Medical Research and Development program supports biomedical research that transforms military and public health...
- The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,477,500 Project Grant to The Schepens Eye Research Institute, Inc., a non-profit organization affiliated with Harvard Medical School and Massachusetts Eye and Ear. The 3-year grant, awarded on September 1, 2023, will fund research on "Topical Calcitonin Gene-Related Peptide for Corneal Injury Prevention and Regeneration." The Schepens Eye Research Institute, which has...
- The U.S. Defense Health Agency awarded a $1,466,706 Project Grant to The Schepens Eye Research Institute, Inc. under the Military Medical Research and Development program (CFDA 12.420). The grant funds research to develop topical oxygen treatments for severe chemical eye injuries, with the goal of providing pan-ocular protection. As a non-profit research organization affiliated with Harvard Medical School and Massachusetts Eye and Ear, Schepens Eye Research Institute has an extensive portfolio...
- This Cooperative Agreement award from the National Eye Institute (CFDA 93.867 - Vision Research) aims to develop a novel fenofibrate-loaded microemulsion (FENO-ME) eyedrop as a non-steroid treatment for nitrogen mustard (NM)-induced corneal injury. The $22,677 award to Virginia Commonwealth University (VCU) spans from Sep 2025 to May 2030. The project seeks to: 1) Validate PPARα signaling as a drug target for NM-induced corneal injury and optimize the FENO-ME eyedrop formulation; 2)...
- The Defense Health Agency awarded a $498,896 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to The Schepens Eye Research Institute, Inc. in Boston, MA. The grant supports a 2-year research project investigating the use of noninvasive transpalpebral electrical stimulation as a therapy for combat-related corneal trauma. As an experienced performer of prior federal grants from agencies like the NIH, DoD, and Army, the non-profit Schepens Eye Research...
- The Department of the Army Medical Command awarded a $1,428,860 Project Grant to The Schepens Eye Research Institute, Inc. of Boston, MA under the Military Medical Research and Development program (CFDA 12.420) to investigate the safety and efficacy of supersaturated oxygen emulsion (SSOE) as a novel topical treatment for open globe injury. The three-year award beginning September 30, 2022 will support animal research using mice to test SSOE and controls supplied by sub-awardee Coruna Medical...